Jonathan Chang Analyst PerformanceSenior Research Analyst at Leerink PartnersJonathan Chang is a stock analyst at Leerink Partners focused in the medical sector, covering 10 publicly traded companies. Over the past year, Jonathan Chang has issued 7 stock ratings, including buy and hold recommendations. While full access to Jonathan Chang's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Jonathan Chang's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings18 Last 8 YearsBuy Recommendations82.35% 14 Buy RatingsCompanies Covered10 Unique Companies Ratings Distribution17RatingsDistribution of strong buy, buy, hold, and sell ratings by Jonathan Chang.RatingPercentageCount Strong Buy0.0%0 ratings Buy82.4%14 ratings Hold17.6%3 ratings Sell0.0%0 ratingsOut of 17 total stock ratings issued by Jonathan Chang at Leerink Partners, the majority (82.4%) have been Buy recommendations, followed by 17.6% Hold.Best & Worst CallsBest Call0000.0%ZLABJun 2019Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%ADAPMar 2018Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ100.0% of companies on NASDAQ10 companiesJonathan Chang, an analyst at Leerink Partners, currently covers 10 companies listed on , with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical9 companies90.0%Manufacturing1 company10.0%Jonathan Chang of Leerink Partners specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE6 companies60.0%MED - DRUGS2 companies20.0%PHARMACEUTICAL PREPARATIONS1 company10.0%BIOTECHNOLOGY1 company10.0% About Jonathan ChangJonathan Chang, Ph.D., CFA is a Senior Research Analyst at Leerink Partners covering Emerging Oncology. He has been an important contributor to the Firm’s biotechnology research product and insights. Jonathan joined the Firm in 2013 as an Associate supporting the Firm’s senior oncology biotechnology research team and in 2016, he assumed research coverage of several important emerging biotechnology companies. In 2018, he was named a Rising Star in Institutional Investor’s 2018 All-America Research Team for Biotechnology/Mid- & Small-Cap. He earned a Ph.D. in Pharmacology from Cornell University, an M.A. in Biotechnology from Columbia University, and an Honors B.Sc. in Genes, Genetics, and Biotechnology from the University of Toronto. Dr. Chang is a CFA charter holder. Jonathan Chang's Ratings History at Leerink Partners Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsWHWKWhitehawk Therapeutics7/13/2026Initiated Coverage$3.97$9.00Outperform$0.0000.00% ROINBTXNanobiotix6/4/2026Boost Price Target$35.20$46.00Outperform$0.0000.00% ROIREPLReplimune Group4/13/2026Reiterated Rating$4.77$2.00Market Perform$0.0000.00% ROIIMTXImmatics12/4/2025Reiterated Rating$10.34$17.00Outperform$0.0000.00% ROINBTXNanobiotix11/25/2025Reiterated Rating$22.00Outperform$0.0000.00% ROIREPLReplimune Group10/20/2025Upgrade$8.97$13.00Outperform$0.0000.00% ROINBTXNanobiotix9/18/2025Set Price Target$11.51$14.00$0.0000.00% ROIREPLReplimune Group7/22/2025Reiterated Rating$2.96$3.00Market Perform$00.0000.00% ROIZLABZai Lab6/30/2025Set Price Target$34.79$75.00Outperform$00.0000.00% ROIGMABGenmab A/S2/13/2025Upgrade$19.69$27.00Outperform$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupCitigroupBarclaysRoyal Bank Of CanadaMorgan StanleyWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenPiper SandlerBMO Capital MarketsDeutsche Bank AktiengesellschaftRaymond James Financial Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
